The combination of ibuprofen and famotidine in NSAID therapy

A phase-3 study, Reduce (Registration Endoscopic Study to Determine Ulcer Formation) performed by dr. Michael Weinblatt and colleagues from Brigham and Women's Hospital in Boston, Massachusetts, United States, giving the conclusion that the therapeutic use of preparations containing a combination of ibuprofen plus famotidine may decrease the side effects of upper GI in patients who memerlukkan therapy with NSAID class of drugs (Nonsteroidal antiinflammatory Drugs). The results of this study have been presented at the annual meeting of the American College of Rheumatology.

Therapeutic use of NSAIDs in these patients effectively manage pain in patients. However, administration of NSAIDs can damage the gastrointestinal mucosa, especially in the stomach and upper small intestine. Whereas in the United States, approximately 43 million sufferers of osteoarthritis and rematoidartritis routinely treated with NSAIDs. Damage to the mucosa can lead to the onset of ulcers and gastrointestinal bleeding. Approximately 30% of patients treated with NSAIDs will have gastrointestinal side effects, and on more than